Drug Trial Radar · NCT07927140
The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Dec 11, 2026
Primary completion
Jan 14, 2030
Study completion Mar 3, 2031
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multi-center, multi-national, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat in pediatric (age ≥2 years to ≤11 years) participants with GD3 who have been treated with ERT for at least 2 years, and have met therapeutic goals. Study details include: Study duration: a 52-week primary analysis period and a 52-week extended treatment period. Treatment frequency: * Daily tablets for venglustat for participants randomized to venglustat arm during primary analysis period and for all patients during extended treatment period. * Cerezyme infusion every 2 weeks for participants randomized to Cerezyme arm during primary analysis period and, if needed, as rescue medication for participants in venglustat treated arm during primary analysis period or for any participant during extended treatment period. Visit frequency: every 12 to 14 weeks during primary treatment period and 12-26 weeks during extended treatment period.
Conditions
- Gaucher's Disease Type III
Interventions
VenglustatDrug
Pharmaceutical form:Tablet-Route of administration:Oral
ImigluceraseDrug
Pharmaceutical form:Sterile lyophilized product vials administered by IV infusion following reconstitution and dilution-Route of administration:IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline in magnetic resonance imaging(MRI) spleen volume (in multiples of normal [MN]) at Week 52Time frame: at Week 52
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.